Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
New Biotechnology|March 20, 2012
Practical perspectives of personalized healthcare in oncologyDarren R Hodgson, Robert Wellings, Christopher Harbron
Molecular Oncology|April 23, 2009
Biomarkers in oncology drug developmentDarren R Hodgson, Robin D Whittaker, Athula Herath, et al.
Molecular Medicine (Cambridge, Mass.)|October 3, 2002
Development of a facile fluorescent assay for the detection of 80 mutations within the p53 geneDarren R Hodgson, Carole A Foy, Maxine Partridge, et al.
Drug Discovery Today|January 5, 2010
Circulating tumour-derived predictive biomarkers in oncologyDarren R Hodgson, Robert Wellings, Maria C M Orr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2016
Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK InhibitorsRoz Brant, Alan Sharpe, Tom Liptrot, et al.
Oncotarget|January 4, 2018
Correlation between MEK signature and Ras gene alteration in advanced gastric cancerSoomin Ahn, Roz Brant, Alan Sharpe, et al.
Nature Reviews. Cancer|April 27, 2016
Defining actionable mutations for oncology therapeutic developmentT Hedley Carr, Robert McEwen, Brian Dougherty, et al.
Oncotarget|May 20, 2017
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance settingBrian A Dougherty, Zhongwu Lai, Darren R Hodgson, et al.
Gynecologic Oncology|November 7, 2021
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trialDarren R Hodgson, Jessica S Brown, Simon P Dearden, et al.
British Journal of Cancer|October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesDarren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
Pageof 2